DCTH DELCATH SYSTEMS, INC.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 872912 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.1%
TTM net income YoY455.4%
TTM EPS YoY433.3%
Revenue 3-yr CAGR270.3%
Net income 3-yr CAGR—
Margins
Gross margin87.6%
Operating margin5.2%
Net margin6.1%
FCF margin18.3%
EBITDA margin5.6%
Returns
ROE5.4%
ROA4.9%
ROIC (approx.)5.6%
Asset turnover0.80x
Leverage & solvency
Liabilities / assets10.4%
Debt / equity0.00x
Current ratio10.87x
Interest coverage—
Cash quality & payout
Operating cash flow / net income3.46x
Accruals ratio-12.0%
Payout ratio—
Capex / revenue2.6%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $35.10M | $29.13M | $24.99M | $20.73M | $20.56M | $24.16M | $19.78M | $15.10M |
| Cost of revenue | $3.92M | $2.98M | $3.74M | $3.01M | $2.62M | $3.32M | $2.85M | $2.13M |
| Gross profit | $31.18M | $26.15M | $21.26M | $17.72M | $17.94M | $20.84M | $16.94M | $12.97M |
| R&D expense | $11.01M | $10.38M | $9.82M | $9.37M | $7.99M | $6.88M | $5.01M | $2.91M |
| SG&A expense | $13.06M | $13.37M | $13.07M | $10.53M | $10.34M | $11.37M | $11.29M | $7.02M |
| Operating income | $7.12M | $2.40M | -$1.64M | -$2.18M | -$388,000 | $2.59M | $642,000 | $3.04M |
| Pretax income | $7.97M | $3.16M | -$908,000 | -$1.33M | $375,000 | $3.21M | $1.26M | -$3.40M |
| Income tax | $1.01M | $491,000 | $162,000 | $562,000 | -$455,000 | $508,000 | $195,000 | $0 |
| Net income | $6.95M | $2.67M | -$1.07M | -$1.90M | $830,000 | $2.70M | $1.07M | -$3.40M |
| EBITDA | $7.32M | $2.50M | -$1.53M | -$2.10M | -$288,000 | $2.69M | $685,000 | $3.08M |
| EPS (basic) | 0.19 | 0.07 | -0.03 | — | 0.02 | 0.08 | 0.03 | — |
| EPS (diluted) | 0.17 | 0.07 | -0.03 | — | 0.02 | 0.07 | 0.03 | — |
| Weighted avg. shares (diluted) | 41.02M | 39.76M | 36.02M | — | 40.06M | 40.26M | 39.51M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $55.54M | $47.52M | $41.31M | $43.45M | $41.81M | $34.42M | $12.78M | $32.41M |
| Short-term investments | $48.78M | $48.38M | $47.99M | $47.58M | $47.10M | $46.58M | $46.12M | $20.82M |
| Receivables | $20.21M | $15.94M | $14.16M | $11.74M | $13.75M | $15.84M | $13.94M | $10.89M |
| Inventory | $10.50M | $11.71M | $9.81M | $10.25M | $10.74M | $10.52M | $7.13M | $6.93M |
| Current assets | $141.56M | $130.54M | $120.27M | $119.53M | $120.61M | $113.48M | $84.35M | $73.76M |
| PP&E, net | $5.13M | $4.02M | $3.66M | $3.17M | $2.71M | $2.40M | $1.95M | $1.79M |
| Total assets | $149.09M | $137.02M | $124.84M | $123.63M | $124.30M | $116.88M | $87.32M | $76.59M |
| Current liabilities | $13.02M | $13.28M | $10.70M | $10.95M | $8.01M | $10.44M | $5.29M | $6.14M |
| Long-term debt | — | — | — | — | — | — | — | $0 |
| Total debt | — | — | — | — | — | — | — | $0 |
| Total liabilities | $15.55M | $15.87M | $12.13M | $12.41M | $9.45M | $11.89M | $7.09M | $7.84M |
| Shareholders' equity | $133.54M | $121.14M | $112.71M | $111.22M | $114.85M | $104.99M | $80.23M | $68.75M |
| Net debt | — | — | — | — | — | — | — | -$32.41M |
| Shares outstanding | 34.77M | 34.64M | 34.47M | 34.69M | 35.31M | 34.96M | 33.44M | 33.06M |
| Cash flow statement | ||||||||
| Operating cash flow | $8.18M | $5.71M | $857,000 | $8.25M | $4.77M | $7.29M | $2.20M | -$1.01M |
| Capital expenditure | $1.26M | $503,000 | $570,000 | $550,000 | $459,000 | $398,000 | $140,000 | $229,000 |
| Free cash flow | $6.92M | $5.21M | $287,000 | $7.70M | $4.31M | $6.89M | $2.06M | -$1.24M |
| Investing cash flow | -$1.26M | -$504,000 | -$571,000 | -$561,000 | -$466,000 | -$415,000 | -$25.15M | -$15.23M |
| Financing cash flow | $1.10M | $962,000 | -$2.38M | -$5.94M | $3.10M | $14.64M | $3.25M | $40.38M |
| Depreciation & amortization | $200,000 | $100,000 | $102,000 | $80,000 | $100,000 | $100,000 | $43,000 | $38,000 |
| Stock-based compensation | $4.23M | $5.12M | $4.95M | $4.51M | $5.65M | $7.21M | $6.86M | $1.61M |
| Share buybacks | $0 | $11,000 | $3.00M | $6.00M | $0 | $0 | $0 | — |
Free plan shows the latest 8 periods; Pro shows all 66 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.